Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Digoxin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Aurobindo Gets FDA Nod for Digoxin Tablets
Details : Digoxin tablets which is inhibiting Na-K ATPase, indicated for the treatment of mild to moderate heart failure in adults, increases myocardial contractility in pediatric patients with heart failure.
Brand Name : Lanoxin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 14, 2022
Lead Product(s) : Digoxin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?